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T hree major trials have supported the efficiency of bronchial thermoplasty (BT) as a safe modality 
that improves the quality of life of patients with severe 
refractory asthma [1-3].  The U.S.  Food and Drug 
Administration approved BT for the treatment of 
refractory asthma in 2010,  and BT has been available in 
Japan since 2015 [4].  The BT procedure reduces the 
smooth muscle mass of peripheral sub-segmental air-
ways by applying radiofrequency energy to large air-
ways.  As an add-on therapy,  BT is an alternative to 
biologic therapies (such as omalizumab and mepoli-
zumab) which can involve more costly pharmacother-
apy [5].  There are still many unanswered questions 
about the selection and management of patients and the 
mechanism of action of BT,  although reductions in air-
way smooth muscle and inflammation have been docu-
mented [6 , 7].  Here,  we explored the clinical charac-
teristics of patients with uncontrolled severe asthma that 
are associated with the effectiveness of BT.
Patients and Methods
Patients. We retrospectively evaluated the patients 
who underwent BT at the National Hospital 
Organization of Okayama Medical Center between June 
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We investigated the clinical characteristics of refractory asthma associated with the effectiveness of bronchial 
thermoplasty (BT).  We retrospectively evaluated data from 10 patients who underwent BT between June 2016 
and December 2017 at Okayama Medical Center.  The following were measured before and 6 months post-BT:  
forced expiratory volume in 1.0 s (FEV1),  fractional exhaled nitric oxide (FeNO),  immunoglobulin E (IgE) 
level,  blood eosinophil counts (Eosi),  Asthma Quality of Life Questionnaire (AQLQ) score,  and preventive 
medication use.  At baseline,  the mean post-bronchodilator FEV1 was 80.9% of the predicted value (range 45.6-
115.7%).  All patients were being treated with moderate- or high-dose inhaled corticosteroids and long-acting 
β2 agonists.  The AQLQ improved from 4.26 ± 1.67 at baseline to 5.59 ± 0.94 at 6 months post-BT (p< 0.05).  The 
%FEV1,  FeNO,  IgE,  and Eosi did not change significantly between baseline and 6 months post-BT.  No severe 
complications were reported.  BT was effective for non-allergic and non-eosinophilic in 3 patients,  and allergic 
or eosinophilic in 4 patients.  Their AQLQ improved by > 0.5 points post-BT.  For both allergic and eosinophilic 
asthmatics following mepolizumab,  BT was not useful.  BT was effective for non-allergic and non-eosinophilic 
or allergic asthmatics,  but insufficient for both allergic and eosinophilic following mepolizumab.
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2016 and December 2017.  The BT was performed in 10 
consecutive patients with severe refractory asthma.  
Severe refractory asthma was defined according to the 
Global Initiative for Asthma (GINA) guideline [8].  The 
following outcomes were measured before and 6 
months after the BT: forced expiratory volume in 1.0 s 
(FEV1),  fractional exhaled nitric oxide (FeNO),  immu-
noglobulin E (IgE) level,  blood eosinophil counts 
(Eosi),  Asthma Quality of Life Questionnaire (AQLQ) 
score,  and preventative medication use.  The study 
protocol was approved by the Institutional Ethics 
Committee of the National Hospital Organization,  
Okayama Medical Center (approval no. H29-RINKEN-
ZINSOKU-009).
Procedures. The BT procedure was performed 
using a flexible bronchoscope (BF-260; Olympus,  
Tokyo).  All proceduralists had been trained in using the 
Alair bronchial thermoplasty system (Boston Scientific,  
Tokyo).  The BT was performed under local and/or gen-
eral anesthesia.  Immediately before the procedure,  an 
inhaled bronchodilator (0.5% salbutamol sulfate 0.3 ml 
or procaterol hydrochloride hydrate 20 μg) and an anti-
sialagogue (atropine 0.25 mg intramuscularly) were 
administered.  For local anesthesia,  2% (w/v) lidocaine 
with sedation drugs (midazolam plus fentanyl) was 
used.  Patients were given prednisone 50mg/day for 3 
days: the day before,  the day of,  and the day after the 
BT procedure.  All patients were electively observed 
in-hospital for 24-48 h after the procedure.
The airways were treated on three separate sessions,  
each 3 weeks apart: the right lower lobe was treated in 
the first session,  the left lower lobe in the second ses-
sion,  and both upper lobes in the final session.  The 
number of radiofrequency activations,  operating times,  
and adverse events were recorded for each treatment 
session.
Statistical analyses. Statistical analyses were per-
formed using Microsoft Office Excel 2010 (Redmond,  
WA,  USA).  Between-group comparisons were made 
using the paired Student’s t-test.  A p-value < 0.05 was 
considered significant.
Results
Table 1 summarizes the baseline characteristics of 
the 10 patients with refractory asthma.  The median age 
was 59 (range 27-74) years.  The mean body mass index 
was 23.5 (range 19.8-26.8) kg/m2.  Eight patients were 
never-smokers,  and two were ex-smokers.  All patients 
were being treated with moderate- or high-dose inhaled 
corticosteroids and long-acting β2 agonists.  Three 
patients (30%) were taking maintenance oral predniso-
lone at < 10 mg/day.  Most of the patients also required 
at least one of the following: montelukast (100%),  
omalizumab (40%),  and mepolizumab (20%).  The 
mean baseline post-bronchodilator FEV1 was 80.9% of 
the predicted value (range 45.6-115.7%); two patients 
(20%) had an FEV1 of < 60% of the predicted value.
All 10 of the patients,  7 women and 3 men,  com-
pleted the BT treatment and the 6-month follow-up 
(Table 2).  Their AQLQ scores improved from 4.26±1.67 
at baseline to 5.59 ± 0.94 at 6 months post-BT (p < 0.05).  
Asthma exacerbations were also reduced significantly 
(baseline 6 months before BT 1.80 ± 1.81 vs. 6 months 
post-BT 0.4 ± 0.51; p < 0.05; values are the mean ±  
standard deviation [SD]),  although the follow-up term 
was only 6 months.  The %FEV1,  FeNO,  IgE,  and Eosi 
values did not change significantly between baseline and 
6 months post-BT.
Table 3 summarizes the %FEV1,  BT technique,  and 
adverse events following BT.  The BT was performed 
under local anesthesia in 4 of the 10 patients,  because 
the patients’ baseline post-bronchodilator FEV1 was 
> 60% of the predicted value.  In 6 of the 10 patients,  
the BT was performed under local and/or general anes-
thesia because of deteriorating lung function and 
patient anxiety.  For Patients 2 , 7,  and 9,  due to a severe 
cough under local anesthesia in the first session,  BT was 
performed under general anesthesia in the other ses-
sions,  uneventfully.  No severe complication was seen 
following the BT.
Patient 1 was treated with systemic corticosteroids 
(125 mg of methylprednisolone sodium succinate) for 
wheezing,  and Patient 3 was treated with antibiotics 
(2 g of ceftriaxone per day in the first session and 
100 mg of sitafloxacin hydrate per day in the other ses-
sions for 4 days) for bacterial pneumonia,  but the 
adverse effects disappeared within 1 week.  Table 4 
summarizes the clinical characteristics of the 10 
patients.  Allergic predominant asthma is defined as 
positivity for at least one of the following: atopy factor 
and specific IgE antigen.  Eosinophilic predominant 
asthma is defined as positivity for at least one of the fol-
lowing:  blood eosinophils > 300 count/μL and mepoli-
zumab therapy before BT [8].
BT was effective for non-allergic and non-eosino-
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philic asthma in Patients 1 , 5,  and 6,  but it was not 
sufficiently effective for both the allergic and eosino-
philic asthma following mepolizumab in Patients 3 and 
8.  The cases of two representative patients for whom BT 
was beneficial are described below.
Patient 1. A 70-year-old woman presented with a 
5-year history of refractory asthma.  She had been char-
acterized as a non-allergic,  non-eosinophilic asthmatic 
(negative results for perennial inhalant allergen sensi-
tivity,  and her IgE and Eosi values before BT were 
155 IU/mL and 110 count/μL,  respectively.  BT was 
performed before biological therapy selection.  The 
patient’s FEV1 showed a tendency to improve,  from 
910 mL (%FEV1 49.4%) to 1,450 mL (%FEV1 82.4%) at 
24 months post-T (Fig. 1).
Patient 2. Patient 2 was a 26-year-old woman 
who had a history of refractory asthma with a severe 
cough for 6 years.  She had been treated with omali-
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Table 1 Patient characteristics (n＝10)
Characteristic Value (range)
Male/female,  n 3/7
Median age (range),  years 59 (27-74)
Mean height (range),  cm 156.7 (145-169)
Mean weight (range),  n 58.2 (44-75)
Mean body mass index (range) 23.5 (19.8-26.8)
Smoking status (never-smoker/ex-smoker),  n 8/2
Nasal comorbidities,  n (%) 2 (20)
Median peripheral eosinophils (range),  count/μL 119 (0-660)
Median immunoglobulin E (range),  IU/mL 94 (45-506)
GINA treatment step (4/5),  n 2/8
Median exacerbations in previous 6 months (range),  n 1 (0-5)
Median baseline AQLQ score 4.40 (1.93-5.96)
Mean FEV1 (range),  mL 1,995 (910-3,130)
Mean %FEV1 (range), % 80.9 (45.6-115.7)
FEV1 ＜60% predicted,  n (%) 2 (20)
Median FeNO (range),  ppb 35 (8-125)
Systemic steroid use,  n (%) 3 (30)
Omalizumab use,  n (%) 4 (40)
Mepolizumab use,  n (%) 2 (20)
Inhaled corticosteroids dose (moderate/high),  n 2/8
LABA/LAMA/LTRA/theophylline use,  n 10/5/10/6
GINA,  Global Initiative for Asthma;  AQLQ,  Asthma Quality of Life Questionnaire; FEV1,  post-bronchodilator forced expiratory volume in 
1.0 s; FeNO,  fractional exhaled nitric oxide;  LABA,  long-acting beta agonists; LAMA,  long-acting muscarinic receptor antagonist; LTRA,  
leukotriene receptor antagonist.
Table 2 Outcomes 6 months after bronchial thermoplasty (BT)
Baseline 6 months after BT P-value
Reduction in drugs used,  n (%) - 4 (40) -
AQLQ 4.26±1.67 5.59±0.94 0.027＊
Proportion with AQLQ change ≧0.5,  n (%) - 7 (70) -
%FEV1,  % 80.9±24.5 77.1±25.5 0.39
FeNO,  ppb 58.6±39.1 59.1±33.6 0.96
Immunoglobulin E,  IU/mL 191.1±174.2 146.7±130.2 0.32
Peripheral eosinophils,  count/μL 213.4±244.1 407.7±308.5 0.062
BT,  bronchial thermoplasty; AQLQ,  Asthma Quality of Life Questionnaire; FEV1,  post-bronchodilator forced expiratory volume in 
1.0 s; FeNO,  fractional exhaled nitric oxide.
＊P＜0.05 was considered to reﬂect statistical signiﬁcance.  Between-group comparisons were made using the paired Studentʼs t-test.  
Values are presented as the mean±standard deviation (SD).
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Table 3 The %FEV1 values,  BT technique,  and adverse events following BT
Patient %FEV1,  % Anesthesia
Operating time
(1/2/3),
minutes
Activation times
(1/2/3),  n Adverse events
1 %FEV1 ＜60% General 27/32/34 42/40/59 Asthma attack
2 %FEV1 ≧60% Local and general 25/20/25 30/38/43 None
3 %FEV1 ＜60% General 25/19/28 30/43/52 Atelectasis,  pneumonia
4 %FEV1 ≧60% Local 16/21/15 17/33/27 None
5 %FEV1 ≧60% Local 20/30/30 30/38/43 None
6 %FEV1 ≧60% Local 25/18/35 25/24/40 None
7 %FEV1 ≧60% Local and general 46/55/48 58/38/85 None
8 %FEV1 ≧60% Local 20/20/30 20/30/56 None
9 %FEV1 ≧60% Local and general 20/20/32 30/30/52 None
10 %FEV1 ≧60% General 35/16/25 31/31/51 None
FEV1,  post-bronchodilator forced expiratory volume in 1.0 s.
The right lower lobe was treated in the ﬁrst session,  the left lower lobe in the second,  and both upper lobes in the ﬁnal session.  No 
adverse events that required additional treatment occurred,  although there was focal bronchitis,  cough,  local wheezing,  and chest dis-
comfort.
Table 4 Clinical characteristics of the patients who underwent BT
Patient Clinicalcharacteristics
Atopy
factor,
n
IgE,
IU/mL
Speciﬁc
IgE antigen,
n
Blood
eosinophils,
count/μL
FeNO,
ppb
Biological
therapy
before BT
AQLQ
before BT
after BT＊
1 Non-allergic
Non-eosinophilic
None 50 None 11 25 None 3.04
5.70
2 Allergic 1 45 2 119 8 Omalizumab 5.84
6.78
3 Allergic
Eosinophilic
2 506 7 0 35 Mepolizumab 5.06
5.00
4 Eosinophilic None 86 0 1,050 133 None 2.12
5.12
5 Non-allergic
Non-eosinophilic
None 89 0 250 35 None 5.81
6.49
6 Non-allergic
Non-eosinophilic
None 236 0 133 11 None 1.93
3.61
7 Allergic 2 94 1 0 25 Omalizumab 5.96
6.47
8 Allergic
Eosinophilic
1 501 1 0 151 Mepolizumab 4.4
4.53
9 Allergic None 171 4 280 88 Omalizumab 5.87
6.25
10 Allergic 1 133 3 291 75 Omalizumab 2.65
6.61
Allergic predominant asthma deﬁnes at least one positive followings: Atopy factor and speciﬁc IgE antigen.  Eosinophilic predominant 
asthma deﬁnes at least one positive followings: Blood eosinophils ＞300 count/μL and mepolizumab therapy before BT.
FEV1,  post-bronchodilator forced expiratory volume in 1.0 s; IgE,  Immunoglobulin E; FeNO,  fractional exhaled nitric oxide; BT,  bronchial 
thermoplasty; AQLQ,  Asthma Quality of Life Questionnaire.
＊6 months after bronchial thermoplasty.
zumab for 2 years,  and she had been characterized as an 
allergic asthmatic (positive results for perennial inhal-
ant allergen sensitivity; her IgE value before BT was 
45 IU/mL).  The omalizumab became unnecessary at 6 
months post-BT (Fig. 2).
Discussion
In randomized clinical trials,  bronchial thermo-
plasty was shown to be a safe,  effective additional 
modality for the management of patients with poorly 
controlled asthma despite standard therapy [1-3].  In 
our present study,  the results of asthma control resem-
bled those of the above-cited trials (Table 2).  A notable 
improvement in FEV1 was observed in Patient 1.  Her 
FEV1 improved from 910 mL (%FEV1 49.4%) to 
1,450 mL (%FEV1 82.4%) at 24 months after the proce-
dure (Fig. 1).  In her case,  BT was performed before 
biological therapy selection because the patient was a 
non-allergic,  non-eosinophilic asthmatic (negative 
results for perennial inhalant allergen sensitivity;  
pre-BT IgE and Eosi were 155 IU/mL and 110 count/
μL,  respectively).  Other research groups have reported 
post-BT improvements in FEV1 [2 , 9].  Langton et al.  
showed that some asthmatic patients with a predicted 
baseline FEV1 < 60% showed a significantly improved 
FEV1 after BT [10].  In the present study,  BT was useful 
for non-allergic and non-eosinophilic asthma in 
Patients 1 , 5,  and 6,  although in Patients 5 and 6 the 
%FEV1 values did not tend to change between baseline 
and 6 months post-BT.  A further prospective study 
would be of interest.
Moreover,  an allergic asthma patient with refractory 
cough (Patient 2) improved following BT,  and omali-
zumab became unnecessary following the procedure 
(Fig. 2).  BT is an alternative to biologic therapies that 
may involve more costly pharmacotherapy [5].  Another 
clinical trial suggested that BT is indicated when severe 
airway hyper-responsiveness and frequent exacerba-
tions persist despite absent or controlled airway inflam-
mation [11].  Kanemitsu et al.  recently reported a 
marked improvement of severe refractory cough by BT 
[12].  Patients whose symptoms might be driven largely 
by airway hyper-responsiveness might benefit from 
smooth muscle-directed therapies,  such as bronchial 
thermoplasty.  In this report,  we did not evaluate the 
cough response to capsaicin.  Moreover,  BT was not 
effective for both allergic and eosinophilic asthma fol-
lowing mepolizumab in Patients 3 and 8 (Table 4).  A 
large-scale trial is required to test the hypothesis that BT 
is not effective for both allergic and eosinophilic 
asthma.
Bronchial thermoplasty has been available in Japan 
since 2015 [4].  The mechanism of action is uncertain,  
but it is known that BT reduces airway smooth muscle 
mass via the delivery of localized thermal energy [2].  
Additional mechanisms of action may contribute to 
symptom reduction,  including structural effects on 
neuroendocrine epithelial cells and bronchial nerve 
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Fig. 1 Time course of %FEV1 values in Patient 1.  The pulmonary 
function showed a tendency to improve at 24 months after BT.  The 
patient was given prednisone 50 mg/day for 3 days: the day before,  
the day of,  and the day after the procedure.  %FEV1,  % post-bron-
chodilator forced expiratory volume in 1.0s; BT,  Bronchial thermo-
plasty.
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Fig. 2 Time course of the AQLQ scores in Patient 2.  Omalizumab 
became unnecessary at 6 months post-BT.  AQLQ,  Asthma Quality 
of Life Questionnaire; BT,  Bronchial thermoplasty.
endings [13].  Future studies will help to define these 
mechanisms [14].  The anesthetic management strate-
gies for BT are also poorly described,  although BT is 
often performed under local anesthesia in Japan.  
Aizawa showed the feasibility and safety of general 
anesthesia for bronchial thermoplasty in Japanese 
patients [15].  In our patients,  BT was performed under 
general anesthesia in the second and third sessions 
uneventfully for Patients 2 , 7,  and 9; the general anes-
thesia was used because of the patients’ severe cough 
under local anesthesia in the first session.  It is unclear 
whether general anesthesia is preferable to topical 
(venous) anesthesia in such patients due to an increased 
risk of CO2 narcosis and complications such as severe 
atelectasis and pneumonia [16].  A further large-scale 
study is needed to clarify this point.
One limitation of our study is that it was a small ret-
rospective analysis.  As the use of BT in clinical practice 
continues to increase in Japan,  it will be necessary to 
create a large clinical dataset to establish the efficiency,  
safety,  and adaptability of BT.
In conclusion,  bronchial thermoplasty was effective 
for non-allergic and non-eosinophilic or allergic asth-
matics,  but it was insufficient for both allergic and 
eosinophilic asthma following mepolizumab treatment.  
The BT procedure might improve asthmatics’ clinical 
condition by a mechanism different from those involv-
ing eosinophils and atopy factor.
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